Monitor for Nasdaq compliance notice and board decision on reverse split ratio and timing. The Yorkville SEPA remains active, meaning further dilution is likely if the company draws on the facility. The $6M market cap and low stock price suggest near-term risk of delisting without a reverse split or capital infusion.
Price Chart
Executive Summary
Jupiter Neurosciences held its 2026 annual meeting, approving a reverse stock split (1:10 to 1:100, board discretion) and a 5.25M-share increase to the equity plan. The 8-K also updates on the Yorkville SEPA financing: ~$1.5M in convertible notes remain outstanding, and ~12.5M shares have been issued for $4.1M net proceeds. The reverse split authorization signals Nasdaq listing concerns, and the ongoing Yorkville facility continues to dilute existing shareholders.
Key Facts
- Stockholders approved a reverse stock split at a ratio between 1:10 and 1:100, with implementation timing and ratio at board discretion.
- Amendment to 2025 Equity Incentive Plan approved, increasing shares available by 5,250,000.
- As of filing, approximately $1.5 million aggregate principal amount of the convertible notes (issued under the SEPA with Yorkville) remains outstanding.
- Company has issued and sold approximately 12.5 million SEPA shares to Yorkville for aggregate net proceeds of approximately $4.1 million.
- The SEPA allows the company to issue up to $20.0 million of common stock to Yorkville over time.
Financial Impact
Continuing dilution from the Yorkville SEPA (up to $20M of shares) and the 5.25M-share equity plan increase; reverse split risk indicates potential Nasdaq non-compliance.
Risk Factors
- Nasdaq delisting if stock price does not recover or reverse split is not implemented in time.
- Further dilution from Yorkville SEPA conversions and equity plan issuances.
- Low market capitalization (~$6M) limits access to traditional capital markets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-034724 |
| Document: 0001493152-26-034724-index-headers.html | 0001493152-26-034724 |
| Document: 0001493152-26-034724-index.html | 0001493152-26-034724 |
| Document: 0001493152-26-034724.txt | 0001493152-26-034724 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G/A | $2.88 | awaiting T+5 | — | $2.71 (−5.83%) |
Sep 24, 2026 4w ago | S-3 | $2.67 $2.55 | ▲ +4.49% | ▲ +4.27% | $2.71 (−1.57%) |
Sep 22, 2026 4w ago | SC 13G | $2.98 $2.58 | ▼ −13.42% | ▼ −12.24% | $2.71 (−8.99%) |
Aug 28, 2026 8w ago | 8-K | $3.54 $3.08 | ▲ +12.99% | ▲ +12.85% | $2.71 (+23.39%) |
Aug 27, 2026 8w ago | 8-K | $4.89 $3.26 | ▲ +33.33% | ▲ +33.60% | $2.71 (+44.54%) |
Aug 24, 2026 9w ago | 8-K | $5.17 $3.35 | ▲ +35.20% | ▲ +34.66% | $2.71 (+47.54%) |
Aug 24, 2026 9w ago | 8-K | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.71 (+52.08%) |
Aug 24, 2026 9w ago | 424B5 | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.71 (+52.08%) |
Jul 27, 2026 13w ago | 8-K | $0.1135 $0.1000 | ▲ +11.89% | ▲ +14.41% | $2.71 (−2289.43%) |
Jul 21, 2026 14w ago | Press Release | $0.1697 $0.1097 | ▼ −35.36% | ▼ −34.36% | $2.71 (+1498.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers